First Quarter

The Bristol-Myers Squibb Foundation commits $290,000 to help the Hungarian Hospice Foundation support psychosocial counseling for cancer patients and their families.

The National Association for Female Executives names Bristol-Myers Squibb one of the Top 30 Companies for Executive Women.

A licensing agreement is signed with Pharmatop—a French company—for injectable acetaminophen.

Abilify (aripiprazole) is launched in Mexico and receives marketing clearance in Australia.

A Bristol-Myers Squibb research and development center opens in Singapore, reinforcing the company’s commitment to R&D in that country and throughout Asia.

Mead Johnson Nutritionals launches Enfamil with Iron and Enfapro in South Korea.

Bristol-Myers Squibb is recognized by several groups for its environmental reporting, including being named the top environmental reporter of all U.S.-headquartered companies by the Coalition of Environmentally Responsible Economies, and being added to the Calvert Social Index, a list of socially responsible companies.

Second Quarter

The U.S. Food and Drug Administration (FDA) approves Reyataz (atazanavir) for marketing—the first once-daily protease inhibitor.

Mead Johnson acquires Cafcit (caffeine citrate) Injection and Oral Suspension, the only FDA-approved short-term treatment for premature infants with a potentially life-threatening breathing disorder.

First Pediatric HIV/AIDS Center in all of Africa opens in Botswana, funded by Bristol-Myers Squibb’s SECURE THE FUTURE® program. The company commits to fund a second center in Africa for children with HIV/AIDS.

The Bristol-Myers Squibb Foundation and its partners—the China Foundation for Hepatitis Prevention and Control and the Chinese Ministry of Health—complete the final phase of a three-year, $510,000 initiative to bring hepatitis B vaccinations to infants in two provinces in rural China.

Third Quarter

Bristol-Myers Squibb and ImClone Systems Incorporated file a Biologics License Application with the FDA for approval of ERBITUX (cetuximab).

The company agrees to license an inhaled insulin product to treat diabetes from QDose, a joint venture between MicroDose Technologies Inc. and Quadrant Drug Delivery Ltd.

ConvaTec introduces Esteem synergy ostomy system in the U.S. It was launched in Europe in 2002.

“Working Mother” magazine names Bristol-Myers Squibb one of the Top 10 Best Companies for Working Mothers for the third straight year. It is also the sixth consecutive year that the company has been included among the magazine’s ranking of the 100 Best Companies.

ChoiceDM, a comprehensive line of diabetic care products, is launched.

Bristol-Myers Squibb and Flamel Technologies S.A. enter into a licensing and commercialization agreement to develop and market Basulin, the first controlled-release, unmodified human insulin to be developed as a once-daily injection for patients with type 1 or type 2 diabetes.

Fourth Quarter

For the fifth time, Bristol-Myers Squibb Brazil is included in the exclusive list of the top 100 companies to work for published by “Exame” magazine—a leading business publication.

Bristol-Myers Squibb and Corgentech Inc. announce an agreement to jointly develop and commercialize Corgentech’s edifoligide, a novel cardiovascular treatment.

Lance Armstrong with members of the Bristol-Myers Squibb TOUR OF HOPE® Team. The 26-member team seeks to raise awareness about cancer research and clinical trials in an unprecedented cross-country cycling journey.

Bristol-Myers Squibb Medical Imaging enters into a U.S. agreement with Fujisawa Healthcare Inc. to copromote Adenoscan (adenosine injection)—the nation’s leading pharmacologic stress agent used in myocardial perfusion imaging.

The company forms an alliance with Lexicon Genetics for neuroscience drug discovery.

Plavix (clopidogrel bisulfate) reaches $2 billion in U.S. sales.